Who are EC Aspirin 325's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo+ASA, Placebo & Aspirin, Enteric-coated aspirin caplets, Low dose ASA, Low-dose acetylsalicylic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ec-aspirin-325.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

EC Aspirin 325 — Competitive Intelligence Brief

EC Aspirin 325 (EC Aspirin 325) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent / NSAID. Area: Cardiovascular.

marketed Antiplatelet agent / NSAID Cyclooxygenase (COX-1, COX-2) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

EC Aspirin 325 (EC Aspirin 325) — POZEN. EC Aspirin 325 is an enteric-coated formulation of aspirin that inhibits platelet cyclooxygenase to prevent blood clots and reduce inflammation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EC Aspirin 325 TARGET	EC Aspirin 325	POZEN	marketed	Antiplatelet agent / NSAID	Cyclooxygenase (COX-1, COX-2)
Placebo+ASA	Placebo+ASA	Peking University Third Hospital	marketed	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1)
Placebo & Aspirin	Placebo & Aspirin	Baim Institute for Clinical Research	marketed	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2)
Enteric-coated aspirin caplets	Enteric-coated aspirin caplets	PLx Pharma	phase 3	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2)
Low dose ASA	Low dose ASA	University of Pennsylvania	phase 3	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1)
Low-dose acetylsalicylic acid	Low-dose acetylsalicylic acid	Barcelona Institute for Global Health	phase 3	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent / NSAID class)

Baim Institute for Clinical Research · 1 drug in this class
Barcelona Institute for Global Health · 1 drug in this class
PLx Pharma · 1 drug in this class
POZEN · 1 drug in this class
Peking University Third Hospital · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EC Aspirin 325 — Competitive Intelligence Brief. https://druglandscape.com/ci/ec-aspirin-325. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab